Biomarkers for molecular risk stratification in prostate cancer

Project start
Institution: Klinik und Poliklinik für Urologie, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden
Applicant: PD Dr. med. Angelika Borkowetz
EKFS funding line: First application
Image Borkowetz

The combination of MRI imaging and prostate biopsy often misses aggressive prostate carcinomas (PCa). Therefore, PCa diagnostics must be improved. Various tumor biological signaling pathways communicate directly with the action of male hormones, which are essential for PCa development. Factors from these signaling pathways are being investigated in blood and urine samples from 400 patients prior to MRI/ultrasound biopsy as potential PCa diagnostic markers. In addition, the distribution of these markers in prostate biopsy tissue will be compared to the presence of the markers in blood and urine to show whether upregulation of the investigated markers can unmask aggressive PCa even in inconspicuous MRI. The prognostic value of these markers will also be analyzed via patient follow-up.

Here you can get further information.